Literature DB >> 27690368

Hereditary Dopamine Transporter Deficiency Syndrome: Challenges in Diagnosis and Treatment.

Yilmaz Yildiz1, Emine Pektas1, Aysegul Tokatli1, Goknur Haliloglu2.   

Abstract

Hereditary dopamine transporter deficiency syndrome (DTDS) is a neurotransmitter disorder caused by a defect in the neuronal uptake of dopamine. To date, 20 patients are reported in the literature, and we present 2 additional patients with DTDS harboring novel homozygous SLC6A3 gene mutations. Patient A is an 8-month-old male with neonatal-onset hypotonia, who developed orolingual dyskinetic movements and oculogyric crises after 4 months of age, with evolution to status dystonicus episodes. Patient B is a 4-year-old male who also had hypotonia since birth, with additional severe limb contractions and oculogyric crises after the age of 3 months, with a misdiagnosis of epileptic encephalopathy. Both patients had consanguineous parents and similar cerebrospinal fluid (CSF) neurotransmitter profiles with elevated homovanillic acid and increased the ratio of homovanillic acid to 5-hydroxyindoleacetic acid. Diagnostic delay is 4 months, and 3 years 9 months, respectively. Treatment response to levodopa is poor. Early infantile-onset progressive dystonia with oculogyric crises, hypotonia, developmental delay, and CSF neurotransmitter profile led to a diagnosis of DTDS in these two patients. Management of hyperkinetic movement disorder, status dystonicus, and feeding difficulties are challenging. Detailed phenotyping of individual patients along with treatment response should provide insight into dopamine homeostasis. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27690368     DOI: 10.1055/s-0036-1593372

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  9 in total

1.  Identifying dominant-negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease.

Authors:  Freja Herborg; Kathrine L Jensen; Sasha Tolstoy; Natascha V Arends; Leonie P Posselt; Aparna Shekar; Jenny I Aguilar; Viktor K Lund; Kevin Erreger; Mattias Rickhag; Matthew D Lycas; Markus N Lonsdale; Troels Rahbek-Clemmensen; Andreas T Sørensen; Amy H Newman; Annemette Løkkegaard; Ole Kjærulff; Thomas Werge; Lisbeth B Møller; Heinrich Jg Matthies; Aurelio Galli; Lena E Hjermind; Ulrik Gether
Journal:  JCI Insight       Date:  2021-09-22

2.  Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.

Authors:  Damiana Leo; Ilya Sukhanov; Francesca Zoratto; Placido Illiano; Lucia Caffino; Fabrizio Sanna; Giulia Messa; Marco Emanuele; Alessandro Esposito; Mariia Dorofeikova; Evgeny A Budygin; Liudmila Mus; Evgenia V Efimova; Marco Niello; Stefano Espinoza; Tatyana D Sotnikova; Marius C Hoener; Giovanni Laviola; Fabio Fumagalli; Walter Adriani; Raul R Gainetdinov
Journal:  J Neurosci       Date:  2018-01-18       Impact factor: 6.167

Review 3.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

4.  Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.

Authors:  Joanne Ng; Serena Barral; Carmen De La Fuente Barrigon; Gabriele Lignani; Fatma A Erdem; Rebecca Wallings; Riccardo Privolizzi; Giada Rossignoli; Haya Alrashidi; Sonja Heasman; Esther Meyer; Adeline Ngoh; Simon Pope; Rajvinder Karda; Dany Perocheau; Julien Baruteau; Natalie Suff; Juan Antinao Diaz; Stephanie Schorge; Jane Vowles; Lucy R Marshall; Sally A Cowley; Sonja Sucic; Michael Freissmuth; John R Counsell; Richard Wade-Martins; Simon J R Heales; Ahad A Rahim; Maximilien Bencze; Simon N Waddington; Manju A Kurian
Journal:  Sci Transl Med       Date:  2021-05-19       Impact factor: 19.319

5.  Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome.

Authors:  P Illiano; C E Bass; L Fichera; L Mus; E A Budygin; T D Sotnikova; D Leo; S Espinoza; R R Gainetdinov
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

6.  Behavioral Phenotyping of Dopamine Transporter Knockout Rats: Compulsive Traits, Motor Stereotypies, and Anhedonia.

Authors:  Stefano Cinque; Francesca Zoratto; Anna Poleggi; Damiana Leo; Luca Cerniglia; Silvia Cimino; Renata Tambelli; Enrico Alleva; Raul R Gainetdinov; Giovanni Laviola; Walter Adriani
Journal:  Front Psychiatry       Date:  2018-02-22       Impact factor: 4.157

Review 7.  A Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting With Movements Disorders.

Authors:  Juan Darío Ortigoza-Escobar
Journal:  Front Neurol       Date:  2020-11-13       Impact factor: 4.003

8.  A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.

Authors:  Shima Kouhnavardi; Alev Ecevitoglu; Vladimir Dragačević; Fabrizio Sanna; Edgar Arias-Sandoval; Predrag Kalaba; Michael Kirchhofer; Jana Lubec; Marco Niello; Marion Holy; Martin Zehl; Matthias Pillwein; Judith Wackerlig; Rita Murau; Andrea Mohrmann; Kathryn R Beard; Harald H Sitte; Ernst Urban; Claudia Sagheddu; Marco Pistis; Roberto Plasenzotti; John D Salamone; Thierry Langer; Gert Lubec; Francisco J Monje
Journal:  Biomolecules       Date:  2022-06-24

Review 9.  Spotlight on Oculogyric Crisis: A Review.

Authors:  Pankaj Mahal; Navratan Suthar; Naresh Nebhinani
Journal:  Indian J Psychol Med       Date:  2020-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.